Table 1. Clinical data of follow-up patients diagnosed with EAML (n = 43).
Baseline data | |
Gender | male/female=25/18 |
Mean age/years | 38.4 (24–76) |
Max diameter | ≤4cm: n=29; 4–7 cm: n=4; 7–10 cm: n=7; ≥10 cm: n=3 |
percentage of epithelioid cells | >90%: n=6; 70–90%: n=9; 5%~70%: n=28. mean: 43.8±22.2 |
percentage of atypia cells | >90%: n=2; 70–90%: n=5 ; 5%~70%: n=36. mean: 28.4±23.1 |
Degree of atypia | severe: n=4; moderate: n=10; low: n=29 |
Necrosis | prominent: 21; focal: 16; little: 6 |
Associated symptoms/signs | backaches: n=6; hematuria: n=2; without: n=35 |
Involvement range | |
confined to kidney(n=35) | Right: n=19 left: n=16 |
beyond kidney (n=6) | perinephric fat: n=3; renal vein: n=2; infraphrenic postcava: n=1 |
distant metastasis(n=2) | liver: n=1; bowel: n=1 |
tumor embolus | (+) for 3 cases (1 in infraphrenic postcava; 2 in renal vein) |
Lymph nodes metastasis | renal hilus node: n=1; renal hilus and para-aortic nodes: n=1 |
Distant metastasis | liver: n=1; bowel: n=1 |
Surgical method | radical nephrectomy: n=12; nephron-sparing surgery: n=30;radical nephrectomy + removal of tumor thrombus in postcava: n=1 |
IHC stain | |
HMB-45$ | 39 (+); 4(focal +) |
Ki-67& | 10 (+, 2–10%); 28 (−); 5 (unclear) |
S100⊠ | 40 (−); 3 (unclear) |
Follow-up data | |
Follow up duration/month | 44.3 (4−71) |
survival status | alive : n=41; dead: n=2 |
Recurrence | One patient with renal hilus node metastasis at baseline suffered local recurrence 10 months postoperatively and died from serious cancer cachexia 4 months later |
Metastasis | One patient suffered metastasis to the liver and lung 12 mons postoperatively and died 17 months after metastasis |
$HMB-45 is a monoclonal antibody that reacts against an antigen present in melanocytic tumors such as melanomas, and means Human Melanoma Black.
&KI-67 is a nuclear protein that is associated with and may be necessary for cellular proliferation.
⊠S100 is a kind of melanoma marker.